Summary
Background: Anastrozole, an aromatase inhibitor, is approved for breast cancer prevention in high-risk women. The long-term effects of aromatase inhibition, including its repurposing potential to other cancers, possible adverse effects, and treatment effect heterogeneity across patient subgroups, remain unclear. Methods: We used the rs727479 variant in CYP19A1 to mimic the effect of long-term pharmacological aromatase inhibition. To evaluate repurposing opportunities, genetic association data on five cancers (211,386 cases, 684,665 controls) were obtained from genome-wide association study consortia. Potential adverse effects were evaluated in a phenome-wide association study (PheWAS) of 449 health-related traits in 162,360 postmenopausal women in the UK Biobank. Effects were investigated across clinically relevant subgroups in the UK Biobank including those defined by body mass index (BMI). Results: Genetically-proxied aromatase inhibition was associated with reduced risk of ER+ breast cancer (OR:0.78, 95%CI:0.67-0.92) and decreased heel bone mineral density (-0.32SD change, 95%CI:-0.36,-0.28). When examining the repurposing potential of anastrozole to other cancers, we found that genetically-proxied aromatase inhibition reduced endometrial cancer risk (OR:0.34, 95%CI:0.26-0.44). In PheWAS, genetically-proxied aromatase inhibition was associated with 6 outcomes (PFDR<0.05) including reduced risk of endometrial polyps (OR:0.58, 95%CI:0.45-0.74) and postmenopausal bleeding (OR:0.67, 95%CI:0.54-0.83), with stronger effects in women with higher BMI (PLRT=1.26x10-3 and 0.02, respectively). Conclusion: Our genetic analyses recapitulate known effects of aromatase inhibition on breast cancer risk and highlight potential repurposing for endometrial cancer prevention. Limited evidence of adverse effects beyond bone mineral density was observed, and subgroup analyses suggested that women with higher BMI may experience greater protection against endometrial conditions.
Outcomes reported
Background: Anastrozole, an aromatase inhibitor, is approved for breast cancer prevention in high-risk women. The long-term effects of aromatase inhibition, including its repurposing potential to other cancers, possible adverse effects, and treatment effect heterogeneity across patient subgroups, remain unclear. Methods: We used the rs727479 variant in CYP19A1 to mimic the effect of long-term pharmacological aromatase inhibition. To evaluate repurposing opportunities, genetic association data on five cancers (211,386 cases, 684,665 controls) were obtained from genome-wide association study consortia. Potential adverse effects were evaluated in a phenome-wide association study (PheWAS) of 449 health-related traits in 162,360 postmenopausal women in the UK Biobank. Effects were investigated across clinically relevant subgroups in the UK Biobank including those defined by body mass index (BMI). Results: Genetically-proxied aromatase inhibition was associated with reduced risk of ER+ breast cancer (OR:0.78, 95%CI:0.67-0.92) and decreased heel bone mineral density (-0.32SD change, 95%CI:-0.36,-0.28). When examining the repurposing potential of anastrozole to other cancers, we found that genetically-proxied aromatase inhibition reduced endometrial cancer risk (OR:0.34, 95%CI:0.26-0.44). In PheWAS, genetically-proxied aromatase inhibition was associated with 6 outcomes (PFDR<0.05) including reduced risk of endometrial polyps (OR:0.58, 95%CI:0.45-0.74) and postmenopausal bleeding (OR:0.67, 95%CI:0.54-0.83), with stronger effects in women with higher BMI (PLRT=1.26x10-3 and 0.02, respectively). Conclusion: Our genetic analyses recapitulate known effects of aromatase inhibition on breast cancer risk and highlight potential repurposing for endometrial cancer prevention. Limited evidence of adverse effects beyond bone mineral density was observed, and subgroup analyses suggested that women with higher BMI may experience greater protection against endometrial conditions.
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.